LL-37 vs PE 22-28
Updated July 21, 2026 · Reviewed by the PeptidesDB Editorial team
A data-driven comparison of LL-37 and PE 22-28 (also searched as PE 22-28 vs LL-37) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.
Verdict
LL-37 centers on healing, while PE 22-28 leans toward metabolic. On indexed research, LL-37 is ahead (LL-37: 5 studies, Human evidence; PE 22-28: 5, Human evidence). Choose by goal — and read the primary studies. This is research information, not medical advice.
Key takeaways
- •LL-37 is strongest for healing; PE 22-28 for metabolic.
- •Evidence: LL-37 Human evidence (5 studies) vs PE 22-28 Human evidence (5).
- •Both are research-use compounds — not FDA-approved.
Effect profiles, overlaid
At a glance
LL-37 vs PE 22-28: side-by-side
| Metric | LL-37 | PE 22-28 |
|---|---|---|
| Class | Immune | Cognitive |
| Regulatory status | Research use only | Research use only |
| Evidence grade | Human evidence | Human evidence |
| Studies indexed | 5 | 5 |
| Research level | Well Studied | Emerging |
| Strongest effect | Healing & recovery | Metabolic & appetite |
| Healing & recovery | 5.0▲ | 2.0 |
| Muscle & body comp | 0.0 | 0.0 |
| Metabolic & appetite | 0.0 | 4.0▲ |
| Neuro & mood | 0.0 | 3.0▲ |
| Sleep & circadian | 0.0 | 0.0 |
| Inflammation & immune | 4.0▲ | 2.0 |
| Skin & aesthetics | 0.0 | 0.0 |
▲ marks the higher community effect score (0–5 perceived-effect signal, not clinical efficacy).
What is LL-37?
### LL-37 Summary LL-37 is a human cathelicidin antimicrobial peptide that plays a crucial role in the innate immune response, exhibiting antimicrobial, immunomodulatory, and wound healing properties. Its diverse functions make it a subject of interest in various fields of biomedical research.
Full LL-37 profile, mechanism & studies →What is PE 22-28?
### Summary PE 22-28 is a peptide that has garnered attention in various research contexts, particularly in relation to vascular health and metabolic conditions. Its potential implications in gestational diabetes and placental function are areas of ongoing investigation.
Full PE 22-28 profile, mechanism & studies →Which is better for your goal?
| Goal | Better fit | Why |
|---|---|---|
| Healing | LL-37 | 5.0/5 effect signal |
| Metabolic | PE 22-28 | 4.0/5 effect signal |
| Neuro | PE 22-28 | 3.0/5 effect signal |
| Inflammation | LL-37 | 4.0/5 effect signal |
Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.
Can you stack LL-37 and PE 22-28?
People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because neither compound is FDA-approved, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.
LL-37 vs PE 22-28: side effects
No community-reported effects logged yet.
No community-reported effects logged yet.
Anonymous community reports (count = number of reports), not clinical incidence rates.
What the research says
LL-37 has 5 approved studies indexed (Human evidence), and PE 22-28 has 5 (Human evidence). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.
Frequently asked questions
Is LL-37 or PE 22-28 better?
It depends on your goal. LL-37 is strongest for healing; PE 22-28 for metabolic. LL-37 has more indexed studies (5). See the goal-by-goal breakdown above.
Is LL-37 or PE 22-28 better for weight loss?
PE 22-28 shows the stronger metabolic & appetite profile (4.0/5) in community effect data — though weight-loss outcomes depend on the individual and the evidence base.
Which has more research, LL-37 or PE 22-28?
LL-37 has 5 approved studies indexed (Human evidence); PE 22-28 has 5 (Human evidence). Higher counts mean more to read, not proven superiority.
Can you stack LL-37 and PE 22-28?
Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.
What are the side effects of LL-37 vs PE 22-28?
LL-37: no community-reported effects logged yet. PE 22-28: none logged yet. These are anonymous reports, not incidence rates — see each profile.
Is LL-37 or PE 22-28 FDA-approved?
LL-37 is a research-use compound and is not FDA-approved. PE 22-28 is not FDA-approved. Research-use status is not a legal clearance to compound or use in humans.
Is PE 22-28 better than LL-37?
For metabolic, PE 22-28 has the edge; for healing, LL-37 does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.
Comparing related peptides
Regulatory & legal status
LL-37 and PE 22-28 are research-use compounds and are not FDA-approved for human use. FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed July 21, 2026.